HepQuant
Share
HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology fo
02/22/2021
Our recent publication in Alimentary Pharmacology & Therapeutics examines the SHUNT test results in relation to the risk of liver decompensation in cirrhotic patients when their disease severity index (DSI) is ≥ 24 or greater. Read more: http://bit.ly/3pOTBb3
Predicting clinical decompensation in patients with cirrhosis using the Hepquant-SHUNT test - PubMed The SHUNT test is a novel, noninvasive test that predicts risk of decompensation in previously compensated patients. DSI ≥24 is independently associated with risk for clinical decompensation, liver transplantation, death and hospitalisation.
Click here to claim your Sponsored Listing.
Website
Address
8110 E. Union Avenue , Suite 750
Denver, CO
80237
Opening Hours
| Monday | 8am - 5pm |
| Tuesday | 8am - 5pm |
| Wednesday | 8am - 5pm |
| Thursday | 8am - 5pm |
| Friday | 8am - 5pm |
